Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) – a new perspective

Mirgh, Sumeet; Sharma, Archana; Folbs, Bhaarat; Khushoo, Vishvdeep; Kapoor, Jyotsna; Tejwani, Narender; Agrawal, Narendra; Choudhary, Partha; Mehta, Pallavi

doi:10.1080/10428194.2021.1941938

Cited by 7 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bortezomib for the constitutive activation of the NF-κB pathway, lenalidomide for IKZF1 depletion, and daratumumab, which targets CD38 overexpression in BPDCN, were used [48][49][50]. Marmouset et al [49] described a promising combination of bortezomib/lenalidomide and dexamethasone in 2019; Mirgh et al [51] demonstrated the efficacy of daratumumab in combination with bortezomib in CD38-positive BPDCN.…”

Section: Multiple Myeloma-based Therapymentioning

confidence: 99%

See 1 more Smart Citation

Plasmacytoid dendritic cell neoplasms

et al. 2023

View full text Add to dashboard Cite

Plasmacytoid dendritic cells (pDCs) are type I interferon-producing cells that modulate immune responses. There are two types of pDC neoplasms: 1) mature pDC proliferation (MPDCP) associated with myeloid neoplasm and 2) blastic pDC neoplasm (BPDCN). MPDCP is a clonal expansion of mature pDCs that is predominantly associated with chronic myelomonocytic leukemia. In contrast, BPDCN is a clinically aggressive myeloid malignancy involving the skin, bone marrow, lymphatic organs, and central nervous system. There are various types of skin lesions, ranging from solitary brown or violaceous to disseminated cutaneous lesions, which often spread throughout the body. The expression of CD4, CD56, CD123, and pDC markers (TCL-1, TCF4, CD303, and CD304, etc.) are typical immunophenotype of BPDCN. Historically, BPDCN treatment has been based on acute leukemia regimens and allogeneic hematopoietic cell transplantation in selected patients. Recent advances in molecular biology and genetics have led to the development of targeted agents, such as tagraxofusp (a recombinant fusion protein targeting CD123), anti-CD123 CAR-T cells, XmAb14045, and IMGN632. Lastly, this review provides a comprehensive overview of pDC neoplasms.

show abstract

Section: Multiple Myeloma-based Therapymentioning

confidence: 99%

“…[ 49 ] described a promising combination of bortezomib/lenalidomide and dexamethasone in 2019; Mirgh et al . [ 51 ] demonstrated the efficacy of daratumumab in combination with bortezomib in CD38-positive BPDCN.…”

Section: Blastic Plasmacytoid Dendritic Cell Neoplasmmentioning

confidence: 99%

Plasmacytoid dendritic cell neoplasms

et al. 2023

View full text Add to dashboard Cite

show abstract

“…A recent case report showed an encouraging clinical response in an elderly BPDCN patient treated with daratumumab-based therapy after prior azacytidine-venetoclax. Daratumumab is an anti-CD38 monoclonal human immunoglobulin G1 antibody that induces cell death and has important immunomodulatory activities in myeloma, which may also play a role in BPDCN [ 41 ].…”

Section: Conventional Therapies and New Therapeutic Options For Bpdcnmentioning

confidence: 99%

Conventional Therapeutics in BPDCN Patients—Do They Still Have a Place in the Era of Targeted Therapies?

Poussard

Angelot‐Delettre

Deconinck

2022

Cancers

View full text Add to dashboard Cite

No benchmark treatment exists for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Since the malignancy is chemo-sensitive, chemotherapy followed by hematopoietic stem cell transplantation remains an effective treatment. However, relapses frequently occur with the development of resistance. New options arising with the development of therapies targeting signaling pathways and epigenetic dysregulation have shown promising results. In this review, we focus on conventional therapies used to treat BPDCN and the novel therapeutic approaches that guide us toward the future management of BPDCN.

show abstract

“…As a monotherapy, daratumumab has been prescribed to elderly patients with BPDCN at a 16 mg/kg weekly dose and elicited rapid responses. 74 , 75 …”

Section: Disease Managementmentioning

confidence: 99%

Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm

Zhang¹,

Sokol²

2022

CMAR

View full text Add to dashboard Cite

Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) – a new perspective

Cited by 7 publications

References 14 publications

Plasmacytoid dendritic cell neoplasms

Plasmacytoid dendritic cell neoplasms

Conventional Therapeutics in BPDCN Patients—Do They Still Have a Place in the Era of Targeted Therapies?

Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm

Contact Info

Product

Resources

About